Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 558

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

Open access
Xu, Cheng, Chen, Yu-Pei, Du, Xiao-Jing, Liu, Jin-Qi, Huang, Cheng-Long, Chen, Lei, Zhou, Guan-Qun, Li, Wen-Fei, Mao, Yan-Ping, Hsu, Chiun, Liu, Qing, Lin, Ai-Hua, Tang, Ling-Long, Sun, Ying, Ma, Jun·2018·BMJ

Abstract

Objective: To provide a complete toxicity profile, toxicity spectrum, and a safety ranking of immune checkpoint inhibitor (ICI) drugs for treatment of cancer. Design: Systematic review and network meta-analysis. Data sources: Electronic databases (PubMed, Embase, Cochrane Library, and Web of Science) were systematically searched to include relevant studies published in English between January 2007 and February 2018. Review methods: Only head-to-head phase II and III randomised controlled trials comparing any two or three of the following treatments or different doses of the same ICI drug were included: nivolumab, pembrolizumab, ipilimumab, tremelimumab, atezolizumab, conventional therapy (chemotherapy, targeted therapy, and their combinations), two ICI drugs, or one ICI drug with conventional therapy. Eligible studies must have reported site, organ, or system level data on treatment related adverse events. High quality, single arm trials and placebo controlled trials on ICI drugs were selected to establish a validation group. Results: 36 head-to-head phase II and III randomised trials (n=15 370) were included. The general safety of ICI drugs ranked from high to low for all adverse events was as follows: atezolizumab (probability 76%, pooled incidence 66.4%), nivolumab (56%, 71.8%), pembrolizumab (55%, 75.1%), ipilimumab (55%, 86.8%), and tremelimumab (54%, not applicable). The general safety of ICI drugs ranked from high to low for severe or life threatening adverse events was as follows: atezolizumab (49%, 15.1%), nivolumab (46%, 14.1%), pembrolizumab (72%, 19.8%), ipilimumab (51%, 28.6%), and tremelimumab (28%, not applicable). Compared with conventional therapy, treatment-related adverse events for ICI drugs occurred mainly in the skin, endocrine, hepatic, and pulmonary systems. Taking one ICI drug was generally safer than taking two ICI drugs or one ICI drug with conventional therapy. Among the five ICI drugs, atezolizumab had the highest risk of hypothyroidism, nausea, and vomiting. The predominant treatment-related adverse events for pembrolizumab were arthralgia, pneumonitis, and hepatic toxicities. The main treatment-related adverse events for ipilimumab were skin, gastrointestinal, and renal toxicities. Nivolumab had a narrow and mild toxicity spectrum, mainly causing endocrine toxicities. Integrated evidence from the pooled incidences, subgroup, and sensitivity analyses implied that nivolumab is the best option in terms of safety, especially for the treatment of lung cancer. Conclusions: Compared with other ICI drugs used to treat cancer, atezolizumab had the best safety profile in general, and nivolumab had the best safety profile in lung cancer when taking an integrated approach. The safety ranking of treatments based on ICI drugs is modulated by specific treatment-related adverse events. Systematic review registration: PROSPERO CRD42017082553.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.k4226

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Cited by

See all 558

Metadata

Authors
Xu, C., Chen, Y.-P., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G.-Q., Li, W.-F., Mao, Y.-P., Hsu, C., Liu, Q., Lin, A.-H., Tang, L.-L., Sun, Y., & Ma, J.
Venue
BMJ
Publisher
BMJ
Published
2018-11-08
Volume
363
Pages
k4226
ISSN
  • 1756-1833 (ISSN-L)
  • 0959-8138
OpenAlex
W2900174742
Cited by
558
References
81
FWCI
6.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1136/bmj.k4226
The paper
Xu, C., Chen, Y.-P., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G.-Q., Li, W.-F., Mao, Y.-P., Hsu, C., Liu, Q., Lin, A.-H., Tang, L.-L., Sun, Y., & Ma, J. (2018). Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ. https://doi.org/10.1136/bmj.k4226

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.